More options available for corneal repair

Article

Corneal transplantation is moving away from penetrating keratoplasty toward less invasive endothelial keratoplasty procedures in which only the damaged portion of the cornea is removed and replaced with donor cells.

Key Points

Chehalis, WA-Corneal transplantation is moving away from penetrating keratoplasty (PK) toward less invasive endothelial keratoplasty (EK) procedures in which only the damaged portion of the cornea is removed and replaced with donor cells, according to David Stanfield, OD, FAAO.

While PK is a well-established procedure that generally produces excellent visual results, it has several drawbacks that have spurred surgeons to develop and modify EK techniques, said Dr. Stanfield, Pacific Cataract and Laser Institute, Chehalis, WA.

Following PK, the possibility that the wound will reopen is a concern for at least a year and potentially for the patient's lifetime. Other issues include corneal irregularities and the risk of infection from sutures. A major drawback with conventional PK is that those patients usually develop significant amounts of induced corneal astigmatism, prolonging visual recovery.

EK options

EK was first performed in the 1950s, but was not pursued aggressively until the late 1990s. Descemet's stripping automated endothelial keratoplasty (DSAEK) and Descemet's stripping endothelial keratoplasty (DSEK) are the most commonly performed EK procedures today, Dr. Stanfield said.

"Early EK procedures-including posterior lamellar keratoplasty (PLK) and deep lamellar endothelial keratoplasty (DLEK)-have been refined as surgeons gained experience. The current menu of procedures includes DSAEK, DSEK, and Descemet's membrane endothelial keratoplasty (DMEK). DSEK and DSAEK have a good track record," he said.

Postoperative visual recovery is usually excellent, and with DMEK, a greater percentage of patients have 20/20 visual acuity compared with traditional PK, DSEK, and DSAEK. Visual rehabilitation typically occurs within a few weeks, compared to a year or more with penetrating keratoplasty.

In DSAEK, donor tissue is transferred to an artificial chamber, an automated microkeratome is activated, and donor tissue is trephined. During DSEK procedures, the donor is manually prepared. Steps for preparing the recipient cornea are stripping and removing the Descemet's membrane, folded insertion of the donor through a small, temporal incision, unfolding the tissue with an air bubble, and removal of some of the air.

In patients undergoing DSAEK or DSEK, the donor endothelium is attached to a small layer of stroma. Although the cornea can be remarkably clear postoperatively in these patients, vision may be less than anticipated, probably due to the fact that the extra stromal layer creates a more irregular optical interface.

Recent Videos
The California Optometric Association and the Los Angeles County Optometric Society have compiled resources for optometrists to get involved in continuing relief efforts.
Dr. Stephanie Woo discusses the upcoming CRU Eye Symposium
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Dr. Ben Casella highlights the importance of SECO to the optometric community.
Dr. Mile Brujic discusses a case series on a novel gel for lacrimal occlusion.
Dr. Julie Rodman discusses retina, imaging, and posterior segment in SECO presentations
Shan Lin, MD, and John Berdahl, MD, share their perspectives as ophthalmologists regarding the importance of comanagement.
© 2025 MJH Life Sciences

All rights reserved.